Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI (MOSAIC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bioiberica
ClinicalTrials.gov Identifier:
NCT01354145
First received: May 13, 2011
Last updated: July 12, 2016
Last verified: July 2016
  Purpose
The main purpose of this study is to compare the cartilage volume loss at the Baseline visit and after 24 months of treatment in patients treated with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily vs. patients treated with CELECOXIB 200 mg daily.

Condition Intervention Phase
Knee Osteoarthritis
Drug: Chondroitin sulfate
Drug: Celecoxib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Twenty-four Month Exploratory Study of the Effect of Chondroitin Sulphate on Structural Changes in Knee Osteoarthritis Patients as Assessed by MRI

Resource links provided by NLM:


Further study details as provided by Bioiberica:

Primary Outcome Measures:
  • Cartilage Volume Loss of the Lateral Compartment [ Time Frame: 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    To compare the cartilage volume loss of the lateral compartment (femoral condyle and tibial plateau) at the Baseline visit and after 12 and 24 months of treatment either with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily or with CELECOXIB 200 mg daily.


Secondary Outcome Measures:
  • Cartilage Volume Loss of the Global Knee [ Time Frame: 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    To compare the cartilage volume loss of the global knee at the Baseline visit and after 12 and 24 months.

  • Cartilage Volume in the Medial Compartment [ Time Frame: 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: Yes ]
    To compare the cartilage volume loss of the medial compartment at the Baseline visit and after 12 and 24 months.

  • Synovial Membrane Thickness [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]

    To compare the severity of synovitis score (Thickness of the Synovial Membrane in mm) in Global Knee , at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.

    The severity of synovitis was evaluated through four regions of interest (ROIs) in the images of the axial T1-weighted acquisition complemented with the use of the images of the axial T2-weighted acquisition. The thickness of the synovial membrane was evaluated in the global knee and each of the ROIs and results were expressed in millimetres. The four ROIs were the proximal lateral, distal lateral, proximal medial and distal medial.


  • Bone Marrow Lesions Score [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]

    To compare the bone marrow lesions (BMLs) score in the global knee and the different sub regions at the baseline visit and the follow-up visits in subjects treated either with CHONDROITIN SULPHATE (CONDROSAN) or CELECOXIB.

    The BMLs were assessed in the global knee and the different sub region of the knee (medial trochlea, plateau of the medial femoro-tibial joint, femur of the medial femoro-tibial joint, medial posterior condyle, lateral trochlea, plateau of the lateral femoro-tibial joint, femur of the lateral femoro-tibial joint, lateral posterior femur). The BMLs score was defined as a grade (between 0 and 3) in each knee sub region and summed to derive a global knee score ranging between 0 (absent) and 30 (present). Specifically, each grade was scored as follows:

    • Grade 0 = Absence of lesion in the sub region
    • Grade 1 = less than 25% of the surface
    • Grade 2 = 25-50% of the surface
    • Grade 3 = more than 50% of the surface

  • Synovial Fluid Volume [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    To compare the synovial fluid volume of the global knee at the Baseline visit and after 24 months.

  • Percentage of Participants With the Presence of Extrusion in the Meniscus [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    The presence of a meniscal extrusion was assessed in each of sub regions. The absence of a severe extrusion in all the sub regions was considered as an absence (score=0) of a severe extrusion in the meniscus. The presence of a severe extrusion in at least one region of the meniscus was sufficient to consider the presence (score=1) of a severe extrusion in the meniscus.

  • Visual Analog Scale (VAS) [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    Visual Analogue Scale: 0 No Pain 10 Maximum Pain Huskisson's VAS measures global pain intensity. Patients were asked to quantify their disease status on a 10 cm VAS as follows: "Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line". Left hand marker represents "No pain" and right hand marker represents "The worst pain imaginable".

  • WOMAC Pain Subscale [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 50 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing.Each item is a 10 cm VAS with 0 and 10 cm representing no pain and extreme pain respectively.

  • WOMAC Stiffness Subscale [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    Western Ontario & McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 20 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day.Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.

  • WOMAC Function Subscale [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    Western Ontario & McMaster Universities Osteoarthritis Index, from 0 No Function to 170 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. Each item is a 10 cm VAS with 0 and 10 cm representing no difficulty and extreme difficulty respectively.

  • Short Form (SF-36) Health Survey [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]

    The SF-36 is composed of 35 items measuring:

    • 8 health concepts (or dimensions), [(Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH)]
    • and 1 reported health transition item.

    The 8 health concepts are summarized in 1 physical (PCS) and 1 mental (MCS) component summary measures. PCS is represented by physical function, role limitations-physical, pain, and general health perception. MCS is represented by vitality, social function, role limitations-emotional, and mental health. Subscale items are summed and scaled from 0-100 to give subscale scores; 0= worst health related quality of life (HRQL), 100=best HRQL. PCS and MCS summary scores are constructed as T-scores (mean =50, standard deviation=10) with no minimum or maximum score; higher scores indicate better health status.


  • Percentage of Participants With Presence of Joint Swelling and Effusion [ Time Frame: Baseline, 12 months (Day 364) and 24 months (Day 728) ] [ Designated as safety issue: No ]
    Study knees were evaluated at each visit for the presence or absence of swelling and effusion.

  • Use of Acetaminophen [ Time Frame: 3 months (Day 91), 6 momnths (Day 182), 12 months (Day 364), 18 monts (Day 546) and 24 months (Day 728) ] [ Designated as safety issue: No ]

    Consumption of Acetaminophen: At each post-baseline visit, the investigator had to assess the consumption of acetaminophen, rescue analgesic authorised throughout the study, by reporting the number of caplets dispensed/retrieved since the previous visit.

    Daily consumption of acetaminophen was calculated as an average.



Enrollment: 194
Study Start Date: June 2011
Study Completion Date: October 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Chondroitin sulfate (Condrosan)
CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
Drug: Chondroitin sulfate
Chondroitin sulphate 1200 mg/day, 24 months treatment period
Other Name: Condrosan
Active Comparator: Celecoxib
CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
Drug: Celecoxib
Celecoxib 200 mg/day, 24 months treatment period

Detailed Description:
To compare long term disease modifiying and symptomatic effects at the Baseline visit and after 24 months of treatment in patients treated with CHONDROITIN SULPHATE 1200 mg daily vs. patients treated with CELECOXIB 200 mg daily.
  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Individuals of either sex, aged 40 years and more
  • Subjects presenting primary OA of the knee according to ACR criteria with signs of synovitis (warmth, swelling or effusion
  • OA of radiological stages 2 and 3 according to Kellgren-Lawrence;
  • Minimum joint space width ≥2 mm in the medial femorotibial compartment on standing knee X-ray
  • VAS of pain while walking ≥ 40 mm

Exclusion Criteria:

  • Known allergy to CHONDROITIN SULPHATE, hypersensitivity to CELECOXIB, demonstrated allergic-type reactions to sulphonamides, experienced asthma, urticaria or allergic-type reactions after taking sulphonamides, aspirin (acetyl salicylic acid [ASA]), lactose or NSAIDs
  • Active malignancy of any type or history of a malignancy within the last five years other than basal cell carcinoma
  • Increased risk for prostate cancer, with prostate cancer, or with a history of prostate cancer within the last five years
  • Subjects with other bone and articular diseases (antecedents and/or current signs) such as chondrocalcinosis, Paget's disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis, Wilson's disease, osteochondromatosis seronegative spondylo-arthropathy, mixed connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel disease
  • Isolated knee lateral compartment OA defined by joint space loss in the lateral compartment only
  • Class IV functional capacity using the American Rheumatism Association criteria
  • Have had surgery in any lower limb or arthroscopy, aspiration or lavage in any lower limb joint within 180 days of the Baseline Visit
  • History of heart attack or stroke, or experienced serious chest pain related to heart disease, or who have had serious diseases of the heart such as congestive heart failure
  • High risk of CV events, according to the AHA assessment of CV risk tables
  • History of recurrent UGI ulceration or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a significant coagulation defect, or any other condition, which in the investigator's opinion might preclude the chronic use of CELECOXIB. Subjects may, at the Investigator's discretion, take a PPI or antacids daily as required
  • Have been diagnosed as having or have been treated for oesophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to receiving the first dose of study medication
  • Subjects using corticosteroids (oral, injectable; exception of intraarticular/soft tissue injection at the exclusion of the target knee), indomethacin, tramadol, codeine, empracet, therapeutic dose of glucosamine or CHONDROITIN SULPHATE during the 12 weeks preceding inclusion
  • Using hyaluronic acid (intra-articular target knee) during the 26 weeks preceding inclusion
  • Using Natural Health Products (e.g. capsaicin, boswellia, willow bark), and creams and analgesic gels (e.g. camphor and alcohol based gels) during one week preceding baseline;
  • Using Natural Health Products susceptible to increase the risk of bleeding (e.g. garlic, dong quai, etc.) during one week preceding baseline;
  • Receiving radioactive synovectomy (target knee) during the 12 weeks preceding inclusion;
  • Subjects who are receiving NSAID and do not want to stop during the study
  • If treatment of osteoporosis (biphosphonates, SERMS, THS) is necessary, it will have to be continued, unmodified, for the entire duration of the study
  • Have used medications with MMP-inhibitory properties (e.g. tetracycline or structurally related compounds) within 28 days prior to the Baseline Visit
  • Are taking lithium carbonate, phenytoin or anticoagulants (with the exception of ASA up to a maximum daily dose of 325 mg)
  • Have received chondrocyte transplants in any lower extremity joint
  • Use oral or topical COXIBs, calcitonin or immunosuppressive drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01354145

Locations
Canada, Quebec
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM)
Montreal, Quebec, Canada, J1H-5N4
Institut de Rhumatologie de Montréal
Montréal, Quebec, Canada, H2L-1S6
Groupe de Recherche en rhumatologie et maladies osseoues
Québec, Quebec, Canada, G1V-3M7
Centre de Rhumatologie St. Louis
Sante Foi, Quebec, Canada, G1W-4R4
Centre de Recherche musculo-squellettique
Trois-Rivières, Quebec, Canada, G8A-1Y2
Sponsors and Collaborators
Bioiberica
Investigators
Study Chair: Jean-Pierre Pelletier, MD Principal Author
  More Information

Responsible Party: Bioiberica
ClinicalTrials.gov Identifier: NCT01354145     History of Changes
Other Study ID Numbers: CS/III-DMOAD-02 
Study First Received: May 13, 2011
Results First Received: February 18, 2016
Last Updated: July 12, 2016
Health Authority: Canada: Health Canada
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Celecoxib
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on December 08, 2016